350 Cambridge Avenue, Suite 350
Palo Alto, CA 94306
December 15, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: | Suzanne Hayes |
Mary Beth Breslin |
Irene Paik |
Re: | Eiger BioPharmaceuticals, Inc. |
FormS-3 Registration Statement |
Registration FileNo. 333-221972 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on FormS-3 (FileNo. 333-221972) to become effective on Wednesday, December 20, 2017, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes each of Glen Sato and Peter Mandel of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Glen Y. Sato of Cooley LLP, counsel to the Registrant, at (650)843-5502, or in his absence, Peter N. Mandel at (650)843-5122.
Very truly yours, | ||
EIGER BIOPHARMACEUTICALS, INC. | ||
By: | /s/ Jim Welch | |
Name: | Jim Welch | |
Title: | Chief Financial Officer |
cc: | David A. Corey,Eiger BioPharmaceuticals, Inc. |
Glen Y. Sato,CooleyLLP |
Peter N. Mandel,CooleyLLP |